Skip to main content

Advertisement

SpringerLink
Go to cart
  • Log in
  1. Home
  2. NeuroRX
  3. Article
Neuroprotection for ischemic stroke: Two decades of success and failure
Download PDF
Your article has downloaded

Similar articles being viewed by others

Slider with three articles shown per slide. Use the Previous and Next buttons to navigate the slides or the slide controller buttons at the end to navigate through each slide.

Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke

30 October 2020

Chengli Liu, Jie Xie, … Wei Wang

Adjunctive cytoprotective therapies in acute ischemic stroke: a systematic review

19 October 2021

I. A. Mulder, E. T. van Bavel, … J. M. Coutinho

Neuronal Death Mechanisms and Therapeutic Strategy in Ischemic Stroke

05 May 2022

Rui Mao, Ningning Zong, … Yun Xu

The Vessel Has Been Recanalized: Now What?

04 April 2023

Johanna Ospel, Nathaniel Rex, … Mayank Goyal

Four Decades of Ischemic Penumbra and Its Implication for Ischemic Stroke

05 July 2021

Shao-Hua Yang & Ran Liu

Cerebrolysin as an Early Add-on to Reperfusion Therapy: Risk of Hemorrhagic Transformation after Ischemic Stroke (CEREHETIS), a prospective, randomized, multicenter pilot study

27 March 2023

Dina R. Khasanova & Mikhail N. Kalinin

Interleukin 1 alpha administration is neuroprotective and neuro-restorative following experimental ischemic stroke

14 November 2019

Kathleen E. Salmeron, Michael E. Maniskas, … Gregory J. Bix

Safety and Optimal Neuroprotection of neu2000 in acute Ischemic stroke with reCanalization: study protocol for a randomized, double-blinded, placebo-controlled, phase-II trial

13 July 2018

Ji Man Hong, Mun Hee Choi, … on the behalf of the SONIC investigators

Current Drug Treatment of Acute Ischemic Stroke: Challenges and Opportunities

11 September 2019

Dafin F. Muresanu, Stefan Strilciuc & Adina Stan

Download PDF
  • Published: January 2004

Neuroprotection for ischemic stroke: Two decades of success and failure

  • Yu Dennis Cheng1,
  • Lama Al-Khoury1 &
  • Justin A. Zivin1,2 

NeuroRX volume 1, pages 36–45 (2004)Cite this article

  • 1334 Accesses

  • 279 Citations

  • 15 Altmetric

  • Metrics details

Summary

Alteplase (rt-PA) is the first therapy successfully developed for acute stroke therapy. The success of rt-PA spurred development of new avenues for acute stroke management. For the last two decades, a great deal of attention has been paid to neuroprotective therapies. Initial preclinical studies demonstrated numerous drugs are effective for treating acute stroke in animal models; however, subsequent clinical trials have been frustrating, and none of the agents has proven effective. The various outcomes of preclinical and clinical trials have been the subject of much discussion. In this article, we review some key neuroprotective trials and the possible reasons for their failures. By identifying the discrepancies between preclinical studies and clinical trials, we may be able to set guidelines for future effective trials.

Download to read the full article text

Working on a manuscript?

Avoid the common mistakes

References

  1. American Stroke Association. Heart Disease and Stroke Statistics-2003 Update. Dallas: American Heart Association, 2003.

    Google Scholar 

  2. Marshall J, Duffin KJ, Green AR, Ridley R. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species.Stroke 32: 190–198, 2001.

    PubMed  CAS  Google Scholar 

  3. Shimizu-Sasamata M, Kano T, Rogowska J, Wolf GL, Moskowitz MA, Lo EH. YM872, a highly water-soluble AMPA receptor antagonist, preserves the hemodynamic penumbra and reduces brain injury after permanent focal ischemia in rats.Stroke 29: 2141–2148, 1998.

    PubMed  CAS  Google Scholar 

  4. Lapchak P et al. A novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits.Stroke 33: 2279–2284, 2002.

    Article  PubMed  CAS  Google Scholar 

  5. Steen P, Newberg LA, Milde JH, Michenfelder JD. Nimodipine improves cerebral blood flow and neurologic recovery after complete cerebral ischemia in the dog.J Cereb Blood Flow Metab 3: 38–43, 1983.

    Article  PubMed  CAS  Google Scholar 

  6. Kidwell CS, Liebeskind DS, Starkman S, Saver JL. Trends in acute ischemic stroke trial through the 20th century.Stroke 32: 1349–1359, 2001.

    PubMed  CAS  Google Scholar 

  7. Zivin JA, Grotta JC. Animal stroke models: they are relevant to human disease.Stroke 21: 981–983, 1990.

    PubMed  CAS  Google Scholar 

  8. Gorelick PB. Neuroprotection in acute ischaemic stroke: a tale of for whom the bell tolls.Lancet 355: 1925–1926, 2000.

    Article  PubMed  CAS  Google Scholar 

  9. Morgenstern LB. What have we learned from clinical neuroprotective trials?Neurology 57: S45-S47, 2001.

    PubMed  CAS  Google Scholar 

  10. Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions.Stroke 33: 2123–2136, 2002.

    Article  PubMed  Google Scholar 

  11. Guyot LL, Diaz FG, O’Regan MH, Song D, Phillis JW. Real-time measurement of glutamate release from the ischemic penumbra of the rat cerebral cortex using a focal middle cerebral artery occlusion model.Neurosci Lett 299: 37–40, 2001.

    Article  PubMed  CAS  Google Scholar 

  12. Boast CS, Gerhardt B, Pastor G, Lehmann J, Etienne PE, Liebman JM. The N-methyl-D-aspartate antagonist CGS19755 and CPP reduce ischemic brain damage in gerbils.Brain Res 442: 345–348, 1988.

    Article  PubMed  CAS  Google Scholar 

  13. Gotti B, Duverger D, Bertin J, Carter C, Dupont R, Frost J et al. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. 1. Evidence for efficacy in models of focal cerebral ischemia.J Pharmacol Exp Ther 247: 1211–1221, 1988.

    PubMed  CAS  Google Scholar 

  14. O’Neill MJ, Hicks C, Ward M. Neuroprotective effects of 7-ni-troindazole in gerbil model of global cerebral ischemia.Eur J Pharmacol 310: 115–122, 1996.

    Article  PubMed  Google Scholar 

  15. Patat A, Molinjier P, Hergueta T, Brohier S, Zieleniuk I, Danjou P et al. Lack of amnestic, psychotomimetic or impairing effect on psychomotor performance of eliprodil, a new NMDA antagonist.Int Clin Psychopharmacol 9: 155–162, 1994.

    Article  PubMed  CAS  Google Scholar 

  16. Aronowski J, Ostrow P, Samways E, Strong R, Zivin JA, Grotta JC. Graded bioassay for demonstration of brain rescue from experimental acute ischemia in rats.Stroke 25: 2235–2240, 1994.

    PubMed  CAS  Google Scholar 

  17. Cohen RA, Hasegawa Y, Fisher M. Effects of a novel NMDA receptor antagonist on experimental stroke quantitatively assessed by spectral EEG and infarct volume.Neurol Res 16: 443–448, 1994.

    PubMed  CAS  Google Scholar 

  18. Muir KW. New experimental data on the efficacy of pharmacological magnesium infusions in cerebral infarcts [abstract].Magnes Res 11: 43–56, 1998.

    PubMed  CAS  Google Scholar 

  19. Saver JL, Kidwell CS, FAST-MAG Trial Group. The Field Administration of Stroke Therapy—Magnesium (FAST-MAG) phase 3 trial. Paper presented at The American Heart Association 27th International Stroke Conference, Ongoing clinical trial session, 2002.

  20. Clark WM, Madden KP, Rothlein R, Zivin JA. Reduction of central nervous system ischemic injury by monoclonal antibody to intercellular adhesion molecule.J Neurosurg 75: 623–627, 1991.

    Article  PubMed  CAS  Google Scholar 

  21. Zhang RL, Chopp M, Jiang N, Tang WX, Prostak J, Manning AM et al. Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat.Stroke 26: 1438–1443, 1995.

    PubMed  CAS  Google Scholar 

  22. Jiang N, Chopp M, Chahwala S. Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat.Brain Res 788: 25–34, 1998.

    Article  PubMed  CAS  Google Scholar 

  23. Ohta K, Graf R, Rosner G, Heiss WD. Calcium ion transients in peri-infarct depolarizations may deteriorate ion homeostasis and expand infarction in focal cerebral ischemia in cats.Stroke 32: 535–543, 2001.

    PubMed  CAS  Google Scholar 

  24. The American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke.Stroke 23: 3–8, 1992.

    Google Scholar 

  25. Mohr JP, Ogogozo JM, Harrison MJG. Meta-analysis of oral nimodipine trials in acute ischemic stroke.Cerebrovasc Dis 4: 197–203, 1994.

    Article  Google Scholar 

  26. Horn J, de Haan R, Vermeulen M, Limburg M. Very early nimodipine use in stroke (VENUS).Stroke 32: 461–465, 2001.

    Article  PubMed  CAS  Google Scholar 

  27. McLean MJ, MacDonald RL. Multiple action of phenytoin on mouse spinal cord neurons in cell culture.J Pharmacol Exp Ther 227: 779–789, 1983.

    PubMed  CAS  Google Scholar 

  28. Ferrendelli JA, Danials-McQueen S. Comparative actions of phenytoin and other antiepileptic drugs on potassium- and veratridine-stimulated calcium uptake in synaptosomes.J Pharmacol Exp Ther 220: 29–34, 1983.

    Google Scholar 

  29. Bebin M, Bleck TP. New anticonvulsant drugs: focus on flunarizine, fosphenytoin, midazolam and stiripentol.Drugs 48: 153–171, 1994.

    Article  PubMed  CAS  Google Scholar 

  30. Gribkoff VK, Starrett JE Jr, Dworetzky SI, et al. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels.Nat Med 7: 471–477, 2001.

    Article  PubMed  CAS  Google Scholar 

  31. Cheng Y, Sun AY. The biomechanisms of kainate-induced neurotoxicity involved in oxidative insult.Neurochemical Res 19: 1557–1564, 1994.

    Article  CAS  Google Scholar 

  32. Lapchak PA, Chapman DF, Zivin JA. Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.Stroke 32: 147–153, 2001.

    PubMed  CAS  Google Scholar 

  33. Haley EC, Kassell NF, Apperson-Hansen C, Maile MH, Alves WM. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America.J Neurosurg 86: 467–474, 1997.

    Article  PubMed  CAS  Google Scholar 

  34. Haley EC Jr. High-dose tirilazad for acute stroke (RANTTAS II). RANTTAS II investigators.Stroke 29: 1256–1257, 1998.

    PubMed  Google Scholar 

  35. D’Orlando KJ, Sandage BW Jr. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury.Neurol Res 17: 281–284, 1995.

    PubMed  Google Scholar 

  36. Schabitz W, Ali F, Irie K, Sandage BW Jr, Locke KW, Fisher M. Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia.Stroke 30: 427–432, 1999.

    PubMed  CAS  Google Scholar 

  37. Clark WM, Warach SJ, Pettigrew LC, Gammans RE, Sabounjian LA. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group.Neurology 49: 671–678, 1998.

    Google Scholar 

  38. Zhao Z, Cheng M, Maples KR, Ma J, Buchan A. NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat.Brain Res 909: 46–50, 2001.

    Article  PubMed  CAS  Google Scholar 

  39. Marshall JWB, Duffin KJ, Green AR, Ridley RM. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species.Stroke 32: 190–198, 2001.

    PubMed  CAS  Google Scholar 

  40. Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)m-ethyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.Stroke 33: 1411–1415, 2002.

    Article  PubMed  CAS  Google Scholar 

  41. Peeling J, Del Bigio MR, Corbett D, Green AR, Jackson DM. Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke.Neuropharmacology 40: 433–439, 2001.

    Article  PubMed  CAS  Google Scholar 

  42. Lees KR, Sharma AK, Barer D, Ford GA, Kostulas V, Cheng YF et al. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke.Stroke 32: 675–680, 2001.

    PubMed  CAS  Google Scholar 

  43. Evans JG, Feuerlein W, Glatt MM, Kanowski S, Scott DB. Chlomethiazole 25 years: recent developments and historical perspectives.Acta Psychiatr Scand Suppl 73[Suppl 327]: 198, 1986.

    Google Scholar 

  44. Green AR. Clomethiazole (Zendra) in acute ischemic stroke: basic pharmacology and biochemistry and clinical efficacy.Pharmacol Ther 80: 123–147, 1998.

    Article  PubMed  CAS  Google Scholar 

  45. Lyden P, Jacoby M, Schim J, Albers G, Mazzeo P, Ashwood T et al. The clomethiazole acute stroke study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results.Neurology 57: 1199–1205, 2001.

    PubMed  CAS  Google Scholar 

  46. Alessandri B, Tsuchida E, Bullock RM. The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat.Brain Res 845: 232–235, 1999.

    Article  PubMed  CAS  Google Scholar 

  47. Cheng Y, Deshmukh M, D’Costa A, Demaro JA, Gidday JM, Shah A et al. Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury.J Clin Invest 101: 1992–1999, 1998.

    Article  PubMed  CAS  Google Scholar 

  48. Endres M, Namura S, Shimizu-Sasamata M, Waeber C, Zhang L, Gomez-Isla T et al. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family.J Cereb Blood Flow Metab 18: 238–247, 1998.

    Article  PubMed  CAS  Google Scholar 

  49. Chen J, Li Y, Wang L, Lu M, Chopp M. Caspase inhibition by Z-VAD increases the survival of grafted bone marrow cells and improves functional outcome after MCAo in rats.J Neurol Sci 199: 17–24, 2002.

    Article  PubMed  CAS  Google Scholar 

  50. Yum SW, Faden AI. Comparison of the neuroprotective effects of the N-methyl-D-aspartate antagonist MK-801 and the opiate-receptor antagonist nalmefene in experimental spinal cord ischemia.Arch Neurol 47: 277–281, 1990.

    PubMed  CAS  Google Scholar 

  51. Graham SH, Shimizu H, Newman A, Weinstein P, Faden AI. Opioid receptor antagonist nalmefene stereospecifically inhibits glutamate release during global cerebral ischemia.Brain Res 632: 346–350, 1993.

    Article  PubMed  CAS  Google Scholar 

  52. Clark WM, Raps EC, Tong DC, Kelly RE. Cervene (Nalmefene) in acute ischemic stroke: final results of a phase III efficacy study. The Cervene Stroke Study Investigators.Stroke 31: 1234–1239, 2000.

    PubMed  CAS  Google Scholar 

  53. Leon A, Lipartiti M, Seren MS, Lazzaro A, Mazzari S, Koga T et al. Hypoxic-ischemic damage and the neuroprotective effects of GM1ganglioside.Stroke 21[Suppl 11]: 11195–1197, 1990.

    Google Scholar 

  54. Carolei A, Fieschi C, Bruno R, Toffano G. Monosialoganglioside GM1 in cerebral ischemia.Cerebrovasc Brain Metab Rev 3: 134–157, 1991.

    PubMed  CAS  Google Scholar 

  55. Argentino C, Sacchetti ML, Toni D, Savoini G, D’Arcangelo E, Erminio F et al. GM1 ganglioside therapy in acute ischemic stroke: Italian Acute Stroke Study—Hemodilusion + drug.Stroke 20: 1143–1149, 1989.

    PubMed  CAS  Google Scholar 

  56. Jessell TM, Sanes JR. The generation and survival of nerve cells. In: Principles of neural science (Kandel ER, Schwartz JH, Jessell TM, eds), pp 1041–1062. New York: McGraw-Hill, 2000.

    Google Scholar 

  57. Zhang Y, Pardridge WM. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system.Stroke 32: 1378–1384, 2001.

    PubMed  CAS  Google Scholar 

  58. Wen TC, Matsuda S, Yoshimura T, Kawabe T, Sakanaka M. Ciliary neurotrophic factor prevent ischemic-induced learning disability and neuronal loss in gerbils.Neurosci Lett 191: 55–58, 1995.

    Article  PubMed  CAS  Google Scholar 

  59. Abe K. Therapeutic potential of neurotrophic factors and neural stem cells against ischemic brain injury.J Cereb Blood Flow Metab 20: 1393–1408, 2000.

    Article  PubMed  CAS  Google Scholar 

  60. Holtzman DM, Sheldon R, Cheng Y, Jaffe W, Ferriero DM. NGF protects the neonatal brain against hypoxic-ischemic injury.Ann Neurol 39: 114–122, 1996.

    Article  PubMed  CAS  Google Scholar 

  61. Cheng Y, Gidday JM, Yan Q, Shah AR, Holtzman DM. Marked age-dependent neuroprotection by brain derived neurotrophic factor against neonatal hypoxic-ischemic brain injury.Ann Neurol 41: 521–529, 1997.

    Article  PubMed  CAS  Google Scholar 

  62. Rosenblatt S, Irikura K, Caday DG, Finklestein SP, Moskowitz MA. Basic fibroblast growth factor (bFGF) dilates rat pial arterioles.J Cereb Blood Flow Metab 14: 70–74, 1994.

    Article  PubMed  CAS  Google Scholar 

  63. Cuevas P, Carceller F, Ortega S et al. Hypotensive activity of fibroblast growth factor.Science 254: 1208–1210, 1991.

    Article  PubMed  CAS  Google Scholar 

  64. Fisher M, Meadows M-E, Do T et al. Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following permanent cerebral ischemia in rats.J Cereb Blood Flow Metab 15: 953–959, 1995.

    Article  PubMed  CAS  Google Scholar 

  65. Jiang N, Finklestein SP, Do T, Caday CG, Charette M, Chopp M. Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduced infarction volume in a model of focal cerebral ischemia/reperfusion in the rat.J Neurol Sci 139: 173–179, 1996.

    Article  PubMed  CAS  Google Scholar 

  66. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system.Science 255: 1707–1710, 1992.

    Article  PubMed  CAS  Google Scholar 

  67. Gould E, Reeves AJ, Graziano MSA, Gross CG. Neurogenesis in the neocortex of adult primates.Science 286: 548–552, 1999.

    Article  PubMed  CAS  Google Scholar 

  68. Takagi Y, Nozaki K, Takahashi J, Ishikawa M, Hashimoto N. Proliferation of neuronal precursor cells in the dentate gyrus is accelerated after transient forebrain ischemia in mice.Brain Res 831: 283–287, 1999.

    Article  PubMed  CAS  Google Scholar 

  69. Nakatomi H, Kuriu T, Okabe S, Yamamoto S, Hantano O, Kawahara N et al. Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors.Cell 110: 429–441, 2002.

    Article  PubMed  CAS  Google Scholar 

  70. Li Y, Chen J, Chopp M. Cell proliferation and differentiation from ependymal, subependymal and choroid plexus cells in response to stroke in rats.J Neurol Sci 193: 137–146, 2002.

    Article  PubMed  Google Scholar 

  71. Modo M, Stroemer P, Tang E, Patel S, Hodges H. Effects of implantation site of stem cell grafts on behavioral recovery from stroke damage.Stroke 33: 2270–2278, 2002.

    Article  PubMed  Google Scholar 

  72. Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons.J Neurosci Res 61: 364–370, 2000.

    Article  PubMed  CAS  Google Scholar 

  73. Li Y, Chen J, Chen XG, Wang L, Gautam SC, Xu YX et al. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery.Neurology 59: 514–523, 2002.

    PubMed  CAS  Google Scholar 

  74. Kondziolka D, Wechsler L, Goldstein S, Meltzer C, Thulborn KR, Gebel J et al. Transplantation of cultured human neuronal cells for patients with stroke.Neurology 55: 565–569, 2000.

    PubMed  CAS  Google Scholar 

  75. The Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest.N Engl J Med 346: 549–556, 2002.

    Article  Google Scholar 

  76. Wang Y, Lim L, Levi C, Heller R, Fisher J. Influence of admission body temperature on stroke mortality.Stroke 31: 404–409, 2000.

    PubMed  CAS  Google Scholar 

  77. Krieger D, De Georgia M, Abou-Chebl, A Andrefsky JC, Sila CA, Katzan IL et al. Cooling for acute ischemic brain damage (COOL AID).Stroke 32: 1847–1854, 2001.

    PubMed  CAS  Google Scholar 

  78. Georgiadis D, Schwarz S, Kollmar R, Schwab S. Endovascular cooling for moderate hypothermia in patients with acute stroke: first results of a novel approach.Stroke 32: 2550–2553, 2001.

    Article  PubMed  CAS  Google Scholar 

  79. Dewar D, Yam P, McCulloch J. Drug development for stroke: importance of protecting cerebral white matter.Eur J Pharmacol 375: 47–50, 1999.

    Article  Google Scholar 

  80. Hunter AJ, Mackay KB, Roger DC. To what extent have functional studies of ischemia in animals been useful in the assessment of potential neuroprotective agents?Trends Pharmacol Sci 19: 59–66, 1998.

    Article  PubMed  CAS  Google Scholar 

  81. Duncan PW, Jorgensen HS, Wade DT. Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice.Stroke 31: 1429–1438, 2000.

    PubMed  CAS  Google Scholar 

  82. Demchuk AM, Buchan AM. Predictors of stroke outcome.Neurol Clin 18: 455–473, 2001.

    Article  Google Scholar 

  83. Grotta JC. Acute stroke therapy at the millennium: consummating the marriage between the laboratory and bedside: the Feinberg lecture.Stroke 30: 1722–1728, 1999.

    PubMed  CAS  Google Scholar 

  84. Zivin JA. Factors determining the therapeutic window for stroke.Neurology 50: 599–603, 1998.

    PubMed  CAS  Google Scholar 

  85. Du C, Hu R, Csernansky CA, Hsu CY, Choi DW. Very delayed infarction after mild focal cerebral ischemia: a role for apoptosis?J Cereb Blood Flow Metab 16: 195–201, 1996.

    Article  PubMed  CAS  Google Scholar 

  86. Jonas A, Aiyagari V, Vieira D, Figueroa M. The failure of neuronal protective agents versus the success of thromolysis for the treatment of ischemic stroke: the predictive value of animal models.Ann NY Acad Sci 939: 257–267, 2001.

    Article  PubMed  CAS  Google Scholar 

  87. Dyker AG, Lees KR. Duration of neuroprotective treatment for ischemic stroke.Stroke 29: 535–542, 1998.

    PubMed  CAS  Google Scholar 

  88. Malakoff D. Bayes offers a “new” way to make sense of numbers.Science 286: 1460–1464, 1999.

    Article  PubMed  CAS  Google Scholar 

  89. Wilson LJT, Hareendran A, Grant M, Baird T, Schulz UG, Muir KW et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified ranking scale.Stroke 33: 2243–2246, 2002.

    Article  PubMed  Google Scholar 

  90. Tilley BC, Marler J, Geller NL, Lu M, Legler J, Brott T et al. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Trial.Stroke 27: 2136–2142, 1996.

    PubMed  CAS  Google Scholar 

  91. Zivin JA, Mazzarella V. Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke.Arch Neurol 48: 1235–1238, 1991.

    PubMed  CAS  Google Scholar 

  92. Bowes MP, Rothlein R, Fagan SC, Zivin JA. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy.Neurology 45: 815–819, 1995.

    PubMed  CAS  Google Scholar 

  93. Lyden PD, Lonzo L, Nunez S. Combination chemotherapy extends the therapeutic window to 60 minutes after stroke.J Neurotrauma 12: 223–230, 1995.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stroke Center, University of California School of Medicine, and University of California San Diego, 92093-0624, La Jolla, California

    Yu Dennis Cheng, Lama Al-Khoury & Justin A. Zivin

  2. Department of Neurosciences, University of California San Diego, 9500 Gilman Drive, 92093-0624, La Jolla, CA

    Justin A. Zivin

Authors
  1. Yu Dennis Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lama Al-Khoury
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Justin A. Zivin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Justin A. Zivin.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cheng, Y.D., Al-Khoury, L. & Zivin, J.A. Neuroprotection for ischemic stroke: Two decades of success and failure. Neurotherapeutics 1, 36–45 (2004). https://doi.org/10.1602/neurorx.1.1.36

Download citation

  • Issue Date: January 2004

  • DOI: https://doi.org/10.1602/neurorx.1.1.36

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Key Words

  • Neuroprotection trials
  • glutamate antagonists
  • anti-inflammatory agents
  • ion channel blocks
  • free radical scavengers
  • neurotrophic factors
  • neural stem cells
Download PDF

Working on a manuscript?

Avoid the common mistakes

Advertisement

Over 10 million scientific documents at your fingertips

Switch Edition
  • Academic Edition
  • Corporate Edition
  • Home
  • Impressum
  • Legal information
  • Privacy statement
  • California Privacy Statement
  • How we use cookies
  • Manage cookies/Do not sell my data
  • Accessibility
  • FAQ
  • Contact us
  • Affiliate program

Not logged in - 95.216.99.153

Not affiliated

Springer Nature

© 2023 Springer Nature Switzerland AG. Part of Springer Nature.